Doctors are looking for better ways to treat triple-negative breast cancer, which is a common and aggressive type of cancer. A large review of data from over 3,000 patients shows that certain medications can help patients live longer and stay healthy.
A specific drug called pembrolizumab showed great results. Patients who received this treatment had about a 34% lower chance of dying from the disease compared to those who did not. It also helped keep the cancer from coming back for a longer period of time.
Another drug called capecitabine also showed promise. While its results on total survival were mixed, it was very effective at keeping the cancer from returning after initial treatment. Using these treatments can provide better outcomes for those facing this specific type of cancer.
These findings suggest that these medications are strong tools for doctors. By using these treatments, medical teams can offer better hope and more effective care to patients with early-stage triple-negative breast cancer.
Common questions
What is the survival benefit of pembrolizumab in early TNBC?
In this meta-analysis, pembrolizumab was linked to a 34% reduction in the risk of death (hazard ratio 0.66, 95% CI 0.64 to 0.79) and a consistent benefit for disease-free survival (hazard ratio 0.63, 95% CI 0.43 to 0.93). This means people taking pembrolizumab had better outcomes, but the analysis cannot prove cause and effect.
Does capecitabine improve overall survival in early TNBC?
The results for capecitabine and overall survival were mixed. The hazard ratio was 0.75 with a 95% confidence interval of 0.55 to 1.03, which means the benefit was not statistically clear. However, capecitabine did show a significant reduction in the risk of recurrence (disease-free survival hazard ratio 0.67, 95% CI 0.52 to 0.88).
What are the side effects of pembrolizumab and capecitabine?
This meta-analysis did not report any safety information, including side effects, serious adverse events, or discontinuations. That means we cannot say anything about how well these drugs were tolerated based on this analysis. For information about side effects, please talk with your doctor.
Who was included in this meta-analysis?
The analysis included 3,133 patients with early-stage triple-negative breast cancer. It looked at treatment with capecitabine and pembrolizumab. The study did not report the setting or follow-up time. Because it is a meta-analysis, it combines results from multiple studies, which can limit how directly the findings apply to any one person.
